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WithYale committing $1 billion to the
development of science and technology
there is much curiosity about how Yale
will spend its money and why Yale is
deciding to spend itnow. Biotechnology in
New Haven, in part, explains Yale?s move
towards the sciences. With the decline in
the New Haven economy since WorldWar
II,Yale stands to benefit greatly ifthe New
Haven economy is revived, in part through
the development of biotechnology. By
investing in biotechnology, Yale hopes to
derive fiscal and intellectual benefit from
the growth of biotechnology, which many
hail as one ofthe engines driving the econ-
omy of the future. With recent attention to
this partnership, it is appropriate to look
more in depth at the ideas that fuel the
local companies joining withYale to forge
a future.
GENAISSANCE
This company merges two disciplines
population genomics and informatics.
Population genomics is the analysis of
inherited differences within diverse groups
of people; informatics is storing, manipu-
lating, analyzing, and visualizing informa-
tion on a computer. Genaissance applies
population genomics to discover inherited
differences, or genomic markers, that are
predictive of which patients will respond
effectively to a drug. Their technology is
based on the discovery and application of
haplotype markers. The Genaissance
approach, dubbed the HAPTm Technology,
combines use of haplotype markers,
known as HAPTM Markers, with a soft-
ware tool, the DecoGenTM informatics sys-
tem and HAPtypingSM Services, for mea-
suring which HAPTm Markers are present
in a patient. Genaissance, with their
HAPTm Technology, hopes to use genomic
variation information to enhance the phar-
maceutical process ofdeveloping, market-
ing and prescribing drugs.
ALEXION
This company focuses on using
human Combinatorial Antibody Library
Technology, "CoALT"' forthe discovery of
highly specific human antibody products.
Alexion's process involves the generation
of combinatorial libraries of human anti-
bodies and the screening of these libraries
against potential drug targets. Alexion
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hopes to use this process to generate novel
human therapeutic antibodies directed at
known clinical targets. Furthermore, Alex-
ion also hopes to use its technology forthe
simultaneous and efficient identification
of both newly discovered genomic targets
and their appropriate antibody therapeu-
tics. By merging this broad enabling dis-
covery platform with Alexion's current
established antibody development capaci-
ty Alexion is poised to start a new wave of
human antibody therapeutics.
VION PHARMACEUTICALS
Vion has three potential anticancer
compounds and a unique targeting vehicle
called TAPET (a genetically modified
tumor-selective Salmonella strain). Vion is
focusing on developing a method for
delivering anticancer drugs (or pro-drug
converting enzymes) directly to the site of
solid tumors via their specialized vector.
Recently published results present data
indicating efficacy in large tumor localiza-
tion ofthe vector and delivery ofpotential
chemotherapeutic agents.
ACHILLION PHARMACEUTICALS
This new company is working on the
"development ofinnovative treatments for
serious infectious diseases." In particular,
Alexion is currently focusing on the treat-
ment of Hepatitis B (HBV), Hepatitis C
(HBC), andHIV/AIDS with several nucle-
oside analogs licensed from Yale. Subse-
quent product candidates, also licensed
from Yale, may address other unmet med-
ical needs, including Epstein-Barr virus
(EBV) infection - the agent causing
infectious mononucleosis in normal young
people and life-threatening lymphoprolif-
erative disorders in immunocompromised
transplant recipients.
CELLULAR GENOMICS, INC.
CGI focuses on identifying potential
targets fordrug development. In particular,
CGI has technologies for identifying
membrane protein drug targets (Mem-
brane 1-Hybrid Program), enzyme drug
targets (Kinase Drug Discovery Program),
and immunomodulatory therapeutics
(Immunology [Dendritic Cell] Program).
Their technology is a series of assays that
are designed to assess and/or discover the
affects of various drugs on the function of
a given membrane protein, enzyme activi-
ty, or the immune response.
MOLECULAR STAGING, INC.
Dubbed RCATb (Rolling Circle
Amplification Technology), RCAT is a
highly sensitive and efficient amplification
method that allows the user to detect the
presence of target molecules in a wide
array oftesting formats. It is an amplifica-
tion method that allows recognition,
amplification and detection of targets
directly on a solid surface, such as within
a cell (in situ analysis) or on a microar-
ray/biochip. MSI claims it to be more ver-
satile and efficient that the polymerase
chain reaction, the current technology
most commonly used to detect genes and
their mutations. Potential target molecules
forRCATinclude the DNA ofabacteria or
virus, a protein produced by cancerous
cells, antibodies to a particular infection,
or a particular sequence of a gene muta-
tion.
PHYTOCEUTICA
PhytoCeutica is focused on develop-
ing novel herbal medicines in the area of
cancer and neurological disease. The two
current drugs, PHY906 and PHY-X are
being developed for use. PHY906 is a
modulator for chemotherapy. It is current-
ly being touted as a treatment for severeShiao: Biotechnology at Yale 199
diarrhea associated with chemotherapies
for colorectal cancer. Current drugs (lop-
eramide/octreotide) are limited in their
treatment of late-onset diarrhea where this
compound is currently being tested for
use. PHY-X is being developed for treat-
ing acute intracerebral hemorrhagic
(AICH) stroke and for other diseases relat-
ed to neurological function impairment.
Currently, there are no pharmaceutical
treatments for AICH patients. Results
from animal studies suggest that PHY-X
can decrease intracranial pressure and can
serve both as an anti-inflammatory and a
neuroprotectant. Human case studies, as
reported by the company, show decreased
mortality rates as well as neurological
function recovery if the drug is adminis-
tered within 24 hours.
RECOMBINANTTECHNOLOGIES
RT functions as a producer and dis-
tributor ofproducts generate by Yale labo-
ratories (such as novel antibodies and
recombinant proteins) as well as a
provider of recombinant technology ser-
vices such as protein purification, assay
development or validation, and protein
functional characterization.
Companies that are not described here
but that have Yale connections include
CuraGen, Agilix, L2 Diagnostics, and
RadioTracer.